Verition Fund Management
SYRE icon

Verition Fund Management’s Spyre Therapeutics SYRE Stock Holding History

Verition Fund Management’s Portfolio SYRE Stock Details SYRE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-48,496
Closed -$813K – 3934
2025
Q3 		$813K Sell
48,496
-16,546
-25% -$270K ﹤0.01% 2692
2025
Q2 		$974K Buy
+65,042
New +$962K ﹤0.01% 2496

Other funds holding SYRE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Verition Fund Management's SYRE Position: Q4 2025 in Review

Verition Fund Management sold out of Spyre Therapeutics (SYRE) in Q4 2025, closing a stake of 48,496 shares — an estimated $813K sold.

Verition Fund Management first reported a position in SYRE in Q2 2025 and held it in 2 quarters. The position peaked at $974K in Q2 2025. 153 funds tracked by Wall St. Rank hold SYRE as of Q4 2025.

  • Verition Fund Management reported no remaining Spyre Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 48,496 Spyre Therapeutics shares in Q4 2025, an estimated $813K.
  • Verition Fund Management first reported a position in Spyre Therapeutics in Q2 2025 and held it in 2 quarters.
  • Verition Fund Management's Spyre Therapeutics position peaked at $974K in Q2 2025.
  • 153 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.